How this company measures up on the fundamentals that matter
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | HASNAIN FAHEEM | Chief Executive Officer | 280,000 | — | |
| 2026-01-02 | GIRAUDO BRYAN M. | Chief Operating Officer | 115,750 | — | |
| 2026-01-02 | PETERSON CARYN | Officer | 84,500 | — | |
| 2026-01-02 | ARANDA RICHARD | Officer | 93,750 | — | |
| 2026-01-02 | CHRISTIAN WAAGE | Officer | 84,500 | — | |
| 2026-01-02 | SMITH ROBERT PAUL JR | Officer | 93,750 | — | |
| 2025-10-01 | HASNAIN FAHEEM | Chief Executive Officer | 437,500 | — | |
| 2025-10-01 | GIRAUDO BRYAN M. | Chief Operating Officer | 181,250 | — | |
| 2025-10-01 | PETERSON CARYN | Officer | 125,000 | — | |
| 2025-10-01 | ARANDA RICHARD | Officer | 162,500 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13